Discussion of Phase 2 IFM 2018-04 Study Data Presented at 2023 ASH Examining DARA+VTd with Tandem ASCT for High Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma

EP: 1.Patient Profile: A 54-Year-Old Woman with Newly Diagnosed Multiple Myeloma

EP: 2.Overview of Results from the DETERMINATION Trial of RVd plus ASCT for Newly Diagnosed Multiple Myeloma

EP: 3.Discussion of Final Analysis of the GRIFFIN Study Comparing DARA+RVd versus RVd

EP: 4.Review of Primary Outcomes from the PERSEUS Trial of Subcutaneous DARA+VRd in Transplant-Eligible Newly Diagnosed Multiple Myeloma

EP: 5.Overview of the IsKia Trial Results Evaluating Isatuximab + KRd in Transplant-Eligible Newly Diagnosed Multiple Myeloma

EP: 6.Summary of Final Analysis from the MASTER Trial of DARA+KRd

Now Viewing

EP: 7.Discussion of Phase 2 IFM 2018-04 Study Data Presented at 2023 ASH Examining DARA+VTd with Tandem ASCT for High Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma

EP: 8.Key Clinical Insights for the Management of Newly Diagnosed Multiple Myeloma

Case: A 54-Year-Old Woman with Newly Diagnosed Multiple Myeloma (NDMM)

Clinical Presentation:

• FH is a 54-year-old woman who presents to her physician with complaints of back pain, fatigue, nausea, constipation, and occasional, but recurring dizziness

Initial Clinical Workup and Diagnosis:

• Hb 7.0 g/dL
• Calcium 11.3 mg/dL
• Creatinine, 1.5 mg/dL
• Albumin, 3.2 g/dL
• β2-microglobulin, 6.0 mg/dL
• LDH 200 U/L
• Bone marrow biopsy showed monoclonal plasma cells, 22%.
• Serum monoclonal protein, 5.0 g/dL
• Serum kappa FLC, 240.0 mg/L
• FISH: (+) IGH Translocations; none
• ECOG PS 1
• AG was diagnosed with R-ISS stage II/R2-ISS stage III IgG-kappa myeloma.
  • CAR T eligible

Treatment:

• Patient was initiated on daratumumab/bortezomib/ lenalidomide/ dexamethasone (D-VRd) induction therapy prior to receiving ASCT, followed by lenalidomide maintenance therapy.
  • She achieved VGPR post-induction, and
  • Maintained VGPR post-ASCT

This is a video synopsis/summary of a Case-Based Peer Perspective featuring: Douglas Sborov, MD.

The phase 2 IFM-2018-04 trial, whose data were presented at the 2023 American Society of Hematology (ASH) annual meeting, included transplant-eligible patients with newly diagnosed multiple myeloma with high-risk cytogenetic abnormalities translocation (4;14), translocation (14;16), or deletion 17p. Patients received 6 cycles of daratumumab-carfilzomib-lenalidomide-dexamethasone (Dara-KRD) induction, stem cell mobilization/collection, autologous stem cell transplant, 4 cycles of Dara-KRD consolidation, a second transplant, then 2 years of Dara-lenalidomide maintenance.

Of 50 patients, 8% had extramedullary disease, 6% had primary plasma cell leukemia, and 60% had 2 or more high-risk features. Post second transplant, 81% achieved a complete response or better and 96% were minimal residual disease negative (10-6 threshold). At 32-month median follow-up, 30-month progression-free survival was 80% and overall survival 91%.

Video synopsis is AI-generated and reviewed by Targeted Oncology® editorial staff.